Phosphatidylserine in Infant Nutrition: Regulatory Status and Documentation Review for US and EU Buyers

Phosphatidylserine has a long commercial history in adult dietary supplements, and that history creates a false sense of transferability. A buyer who has qualified PS for a 300 mg adult capsule often assumes the same specification can be dropped into an infant product with a few extra tests. It cannot.

The reason is not that PS is problematic. It is that food intended for infants is the most tightly composed category in food law. The test is never whether an ingredient is safe in general but whether it is permitted for this use, at this level, in this market.

This review separates three questions buyers routinely conflate: what PS is used for today in adults, what would legally be required in infant or follow-on formula, and what a supplier can honestly document. The answers point in different directions.

Why Infant and Toddler Nutrition Is a Separate Regulatory Category

Infant nutrition law prescribes composition rather than merely constraining it. In the EU, food for infants and young children sits under Regulation (EU) No 609/2013, with Commission Delegated Regulation (EU) 2016/127 setting the compositional and information requirements for infant formula and follow-on formula. Substances that may be added are essentially enumerated; being safe, or being sold elsewhere in the food supply, is not enough.

In the US, infant formula is governed by section 412 of the FD&C Act and 21 CFR Parts 106 and 107. Every ingredient must be an approved food additive or generally recognized as safe, and suitable for such use. That last clause carries weight: a GRAS conclusion covering an adult supplement does not address suitability where the product may be an infant's sole source of nutrition for months.

Feasibility is therefore a legal question answered before it becomes a technical one.

United States: The Infant Formula Submission Pathway Versus the Supplement Pathway

Think of two separate doors. The supplement door is familiar: adult supplements are made under 21 CFR Part 111 GMP, and the ingredient needs GRAS status or an accepted new dietary ingredient history for the marketed use. PS has an established history here, including the GRAS and NDI history associated with soy-derived PS. Verify the status of any conclusion against FDA's records and with your own counsel, because these are ingredient- and use-specific.

The infant formula door is different. FDA does not approve formulas, but a manufacturer must notify the agency through a new infant formula submission covering composition and the basis on which each ingredient meets the standard; adding a previously unused ingredient generally triggers its own submission. Part 106 also imposes CGMP requirements, quality-factor obligations including growth monitoring and protein biological quality, and Salmonella and Cronobacter testing.

Imported formula meets the same requirements, and the US importer carries verification obligations under the Foreign Supplier Verification Programs rule. No supplier can discharge that for you; it can only supply evidence for your filing.

European Union: A Closed Composition List Plus the Novel Food Question

Composition comes first. Under Regulation (EU) 2016/127, only substances meeting its provisions or falling within the EU permitted-substance framework for food for specific groups may be added to formula, subject to purity criteria. PS is not an established compositional ingredient in EU infant formula, and there is no default route to add it.

Then novel food. Regulation (EU) 2015/2283 requires authorisation for foods lacking a significant EU consumption history before 15 May 1997, assessed against the specific use and use level rather than the molecule in the abstract. For PS, assessments have historically turned on source material, production process, food category, and dose; soy-derived and sunflower-derived PS have travelled different paths, and member-state views have not always aligned.

Do not rely on a supplier summary here. Search the Commission's Novel Food Catalogue and the Union list of authorised novel foods directly, record date-stamped evidence, and confirm the position with the competent authority in the member state of first placement.

Why Existing Phosphatidylserine History Does Not Transfer to Infants

Three pieces of PS history are regularly over-read. The early-2000s US qualified health claim is heavily qualified, framed for adults on limited and preliminary evidence, and neither addresses infants nor authorises any formula use. Paediatric research in school-age children supports a dossier but never substitutes for one. And a GRAS determination is scoped by intended use and use level: an unremarkable intake in a 70 kg adult is a materially different dose per kilogram in a 4 kg infant.

Where PS does have realistic near-term room is in adjacent categories — maternal and prenatal supplements and adult nutrition. Teams with an infant ambition often find maternal positioning executable on a realistic timeline.

A Documentation Due-Diligence Checklist for Buyers

Define the target product — infant formula, follow-on formula, young-child food, or maternal supplement — record the governing legal category for each market, and fix the country of first sale.

Collect the evidence: a written regulatory opinion; a date-stamped Novel Food Catalogue and Union list check for the EU; for the US, the intended Part 106 submission route and change-control trigger analysis; and the PS identity file covering botanical source, assay basis and method, carrier level, residual solvent, GMO status, and allergen status including soy protein carryover.

Set analytical requirements tighter than a standard supplement specification: individual heavy metals with named methods and applicable EU maximum levels confirmed; microbiology including Salmonella and Cronobacter for powders; Enterobacteriaceae and viable counts; peroxide value across the full shelf life; and a valid food contact declaration for every liner or bag.

From the supplier, request the whole picture rather than a headline sheet: complete specification with named methods, a COA for a named recent lot, process flow identifying process aids and allergen controls, a change-control commitment covering source, process and site, one-back-one-forward traceability, and the food safety certificate with its site scope.

What a Responsible Supplier Can and Cannot State

A credible PS supplier will put three things in writing. It will state what the material is: source, assay basis and method, per-lot impurity limits, allergens, GMO position, residual solvent history, packaging and storage conditions, and food contact status for every contact material. It will state what it knows and does not know about downstream regulatory status.

And it will decline to say that PS is approved for infant formula in the EU or cleared in the US, because that statement would be false. Treat an unqualified assurance as a signal about the supplier rather than as a compliance answer.

FAQ

Q: Is phosphatidylserine authorised for use in EU infant formula?

A: Do not assume so. EU composition rules operate from a permitted-substance basis under Regulation (EU) 2016/127, and PS is not an established compositional ingredient in infant formula. Check the Novel Food Catalogue and the Union list of authorised novel foods, and confirm the position with the competent authority.

Q: Can we use our existing adult GRAS position for PS in a US infant formula?

A: Not by itself. Ingredients must meet the food-additive or GRAS standard and be suitable for such use, assessed in the infant-formula context. Adding a new ingredient also generally triggers a new Part 106 submission. Confirm the route with counsel.

Q: What is the realistic alternative if a formula project is blocked?

A: Maternal, prenatal, and adult supplements, where PS already has commercial history and documentation. Teams frequently re-scope an infant concept into maternal positioning while evaluating a formal authorisation route.

Q: Which specification lines matter most for an infant-adjacent application?

A: Heavy metals with named methods, microbiology including Salmonella and Cronobacter for powders, peroxide value across the stated shelf life, full source and allergen disclosure, and food contact declarations for the packaging.

Q: Should we accept a supplier's verbal assurance of regulatory status?

A: No. Require a written position separating what the supplier warrants about the material from what it knows about downstream use, and have uncertain points confirmed in writing by counsel and the competent authority.

Conclusion

Phosphatidylserine is a well-characterised phospholipid with a real commercial record in adult and maternal nutrition, and it is not an authorised infant-formula ingredient by default in either the United States or the European Union. Both statements are true.

The right sequence is category, jurisdiction, documentation, then sample. Buyers working in that order either find a viable route quickly — usually maternal positioning — or learn early that the formula route needs authorisation work belonging to the brand owner.

Nutranexa answers these questions plainly: what the material is, what it can be documented to support, and where you need your own advice.

Sources

• U.S. Food and Drug Administration (FDA) — Infant Formula home page (notification requirements, ingredient and nutrient requirements, Salmonella and Cronobacter testing): https://www.fda.gov/food/resources-you-food/infant-formula
• U.S. Food and Drug Administration (FDA) — Food programme home page: https://www.fda.gov/food
• Electronic Code of Federal Regulations (eCFR) — 21 CFR Part 106, Infant Formula Requirements: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-106
• Electronic Code of Federal Regulations (eCFR) — 21 CFR Part 107, Infant Formula: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-107
• U.S. Food and Drug Administration (FDA) — Current Good Manufacturing Practice for Dietary Supplements (21 CFR Part 111): https://www.fda.gov/food/current-good-manufacturing-practice-cgmp-dietary-supplements
• European Union — Commission Delegated Regulation (EU) 2016/127 on infant formula and follow-on formula: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016R0127
• European Union — Regulation (EU) No 609/2013 on food intended for infants and young children and for special medical purposes: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32013R0609
• European Union — Regulation (EU) 2015/2283 on novel foods: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32015R2283
• European Commission — Food Safety portal, including EU food law, novel food, and food for specific groups: https://food.ec.europa.eu/index_en
• European Food Safety Authority (EFSA) — scientific opinions and novel food assessments: https://www.efsa.europa.eu/en

Étapes suivantes recommandées

• Passez en revue le Phosphatidylserine page produit.
• Comparer Soy PS et Sunflower PS.
• Vérifier preuve de fabrication et Qualité & R&D.